Mickaël Aoun, MD

Head of the Infectious Diseases
Institut Jules Bordet

Disclosure: Amplyx Pharmaceuticals (Individual(s) Involved: Self): Scientific Research Study Investigator

Presentation(s):

• 147 - Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

  Oral Abstract